CoQ10 vs Ubiquinol: Which Form Should You Actually Buy?

CoQ10 vs Ubiquinol: Which Form Should You Actually Buy?

Coenzyme Q10 (CoQ10) is one of the most popular supplements sold in the UK, and for good reason: it plays a central role in mitochondrial energy production and is significantly depleted by statin medications — the most widely prescribed drugs in Britain. But walk into any health food shop and you will face a choice between two forms: ubiquinone and ubiquinol. The marketing often implies that ubiquinol is vastly superior, but the scientific picture is more nuanced than the price differential (ubiquinol typically costs considerably more) might suggest.

What Is CoQ10 and Why Does It Matter?

CoQ10 (also written as coenzyme Q10 or coenzyme Q) is a lipid-soluble molecule synthesised in every human cell. Its primary function is as an electron carrier in the mitochondrial respiratory chain — specifically shuttling electrons from Complex I and Complex II to Complex III, a step essential for producing ATP via oxidative phosphorylation. Without adequate CoQ10, mitochondrial efficiency falls and ATP production is impaired.

Beyond its role as an electron carrier, CoQ10 functions as a lipid-soluble antioxidant, protecting cell membranes and LDL particles from oxidative damage.

CoQ10 is particularly concentrated in metabolically demanding tissues: the heart, liver, kidney, and skeletal muscle. Cardiac tissue contains some of the highest CoQ10 concentrations in the body, which is why CoQ10 has attracted the greatest clinical interest in cardiovascular and neuromuscular contexts.

Ubiquinone vs Ubiquinol: Chemistry

CoQ10 exists in two redox states. Ubiquinone is the oxidised form — this is what most CoQ10 supplements historically contained and what the body synthesises internally. Ubiquinol is the reduced form, carrying two extra hydrogen atoms. In the respiratory chain, CoQ10 cycles continuously between these two forms: it accepts electrons (becoming ubiquinol) and then donates them (reverting to ubiquinone).

In healthy young adults, approximately 90–95% of plasma CoQ10 is in the ubiquinol (reduced) form — the body efficiently converts ubiquinone to ubiquinol. Ubiquinol manufacturers argue that in older adults and those with impaired mitochondrial function, this conversion becomes less efficient, and providing ubiquinol directly bypasses this bottleneck.

Bioavailability: Does Form Matter?

Several pharmacokinetic studies have compared ubiquinone and ubiquinol absorption directly. Generally, ubiquinol shows somewhat better relative bioavailability in healthy adults when compared at lower doses. A 2009 study by Bhagavan and colleagues found that ubiquinol produced approximately 50% higher peak plasma CoQ10 concentrations than ubiquinone at a 200mg dose.

However, this advantage narrows considerably at higher doses of ubiquinone and when ubiquinone is formulated in oil-based softgels (which substantially improve absorption over powder capsules). A 100–200mg dose of well-formulated oil-based ubiquinone achieves meaningful plasma elevation in most adults. The bioavailability advantage of ubiquinol is real but may not be as dramatic as supplement marketing implies — particularly in healthy individuals with intact reduction capacity.

For older adults (over 65) or those with compromised mitochondrial function, the conversion argument has more merit, making ubiquinol a more defensible choice in these populations.

The Q-SYMBIO Trial: Landmark Cardiovascular Evidence

The most important clinical trial for CoQ10 in cardiovascular disease is Q-SYMBIO, a randomised, double-blind, multicentre trial published in JACC Heart Failure in 2014. This was conducted in 420 patients with severe chronic heart failure across nine countries over two years.

Patients received 300mg of ubiquinone daily (100mg three times with meals) or placebo. The results were striking: the CoQ10 group showed:

- 43% reduction in Major Adverse Cardiovascular Events (MACE), including cardiovascular death and hospitalisation - Significant reduction in all-cause mortality (18 deaths vs 9 deaths in the two-year period, though absolute numbers were small) - Improved symptom scores and reduced need for hospitalisation

Q-SYMBIO used ubiquinone, not ubiquinol. This is important context when evaluating ubiquinol's theoretical superiority: the most significant human trial demonstrating cardiovascular benefit used the supposedly inferior form. This doesn't mean ubiquinol performs worse, but it does suggest that well-dosed ubiquinone is clinically active and effective.

Statins and CoQ10 Depletion

This is perhaps the most clinically significant application of CoQ10 supplementation in general use. Statins inhibit HMG-CoA reductase — the same biochemical pathway responsible for CoQ10 synthesis in the body. Plasma CoQ10 levels fall by approximately 40–50% in patients taking statins, and this depletion has been proposed as a contributor to statin-associated myopathy (muscle pain and weakness), which affects 10–25% of statin users.

The clinical trial evidence on whether CoQ10 supplementation reduces statin myopathy is mixed — some trials show benefit, others do not, and the heterogeneity in patient populations, CoQ10 doses, and statin types used complicates interpretation. A 2015 meta-analysis by Banach and colleagues found a statistically significant reduction in statin-associated muscle pain with CoQ10 supplementation compared to placebo.

Regardless of the myopathy evidence, restoring plasma CoQ10 to pre-statin levels seems prudent in long-term statin users, given CoQ10's fundamental role in mitochondrial function.

Dosing and Practical Guidance

For general cardiovascular support and statin co-supplementation, 100–200mg daily in oil-based softgels is the commonly used range. For heart failure or more intensive support, the Q-SYMBIO trial used 300mg daily in divided doses.

CoQ10 should always be taken with a meal containing fat — it is lipophilic and absorption is substantially increased with dietary fat co-ingestion.

Bottom Line

Both ubiquinone and ubiquinol are effective forms of CoQ10. Ubiquinol may offer modest bioavailability advantages, particularly in older adults. However, the landmark Q-SYMBIO trial demonstrating a 43% reduction in cardiovascular events used ubiquinone — evidence that well-formulated ubiquinone is clinically active. At 100–200mg daily in oil-based softgels, CoQ10 is particularly well evidenced for statin users, those with heart failure, and anyone with high mitochondrial demand.